|
Dr. Ansbert Gadicke is the Founder and a General Partner of the MPM Group. He led MPM’s effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an MD from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University, and the German Cancer Research Center. He has published in leading scientific publications, including Nature and Cell. Dr. Gadicke is a Director of Arriva Pharmaceuticals, Inc., Cerimon Pharmaceuticals, Inc., Elixir Pharmaceuticals Inc., Omrix Biopharmaceuticals, Inc., Nuvios, Inc., Pharmasset, Inc., PharmAthene, Inc., and Xanodyne Pharmaceuticals, Inc. He previously served as a Director of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Coelacanth Corporation, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), Kourion Therapeutics AG, MediGene AG (Frankfurt: MDG), Viacell, Inc. (Nasdaq: VIAC), and TransForm Pharmaceuticals, Inc. He is a member of Advisory Councils for Harvard Medical School and the Whitehead Institute at MIT. Dr. Gadicke serves as the Co-Chairman of the Alumni Association of the Whitehead Institute and serves on the Board of the National Venture Capital Association (NVCA). | 